These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9692403)

  • 21. [Hepatic abscess due to Yersinia in a child with thalassemia].
    Brunel F; François P; Durand C; Croize J; Jeannoel P
    Pediatrie; 1993; 48(2):159-62. PubMed ID: 8393182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy.
    Cianciulli P; Sollecito D; Sorrentino F; Forte L; Gilardi E; Massa A; Papa G; Carta S
    Kidney Int; 1994 Aug; 46(2):467-70. PubMed ID: 7967359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deferoxamine treatment during early pregnancy: absence of teratogenicity in two cases.
    Vaskaridou E; Konstantopoulos K; Kyriakou D; Loukopoulos D
    Haematologica; 1993; 78(3):183-4. PubMed ID: 8375749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ocular involvement correlated with age in patients affected by major and intermedia beta-thalassemia treated or not with desferrioxamine.
    Rinaldi M; Della Corte M; Ruocco V; D'Onofrio C; Zanotta G; Romano A
    Metab Pediatr Syst Ophthalmol (1985); 1993; 16(1-2):23-5. PubMed ID: 8259071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
    Athanassiou-Metaxa M; Tzimouli V; Economou M; Taparkou A; Tourkantoni N; Kanakoudi-Tsakalidou F
    Acta Haematol; 2003; 110(4):224-6. PubMed ID: 14663175
    [No Abstract]   [Full Text] [Related]  

  • 28. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature.
    Tam DH; Farber HW
    Am J Hematol; 2006 Jun; 81(6):443-7. PubMed ID: 16680745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a new method of administration of the iron chelating agent deferoxamine.
    Borgna-Pignatti C; Cohen A
    J Pediatr; 1997 Jan; 130(1):86-8. PubMed ID: 9003855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current treatment of Cooley's anemia. Intravenous chelation therapy.
    Cohen AR; Martin M; Schwartz E
    Ann N Y Acad Sci; 1990; 612():286-92. PubMed ID: 2291556
    [No Abstract]   [Full Text] [Related]  

  • 33. Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience.
    Songdej D; Sirachainan N; Wongwerawattanakoon P; Sasanakul W; Kadegasem P; Sungkarat W; Chuansumrit A
    Acta Haematol; 2015; 133(2):226-36. PubMed ID: 25376266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major.
    Miller TT; Caldwell G; Kaye JJ; Arkin S; Burke S; Brill PW
    Pediatr Radiol; 1993; 23(7):523-4. PubMed ID: 8309753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity.
    Bentur Y; Koren G; Tesoro A; Carley H; Olivieri N; Freedman MH
    Clin Pharmacol Ther; 1990 Apr; 47(4):478-82. PubMed ID: 2328556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
    Brittenham GM; Griffith PM; Nienhuis AW; McLaren CE; Young NS; Tucker EE; Allen CJ; Farrell DE; Harris JW
    N Engl J Med; 1994 Sep; 331(9):567-73. PubMed ID: 8047080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical resection of multiple right atrial masses in a child with beta thalassaemia and receiving desferioxamine.
    West M; Malik GA; Pollock JC
    Heart; 2003 May; 89(5):501. PubMed ID: 12695451
    [No Abstract]   [Full Text] [Related]  

  • 38. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
    Arandi N; Haghpanah S; Safaei S; Zahedi Z; Ashrafi A; Eatemadfar P; Zarei T; Radwan AH; Taher AT; Karimi M
    Transfus Med; 2015 Feb; 25(1):8-12. PubMed ID: 25801075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
    Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
    Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
    Bachelot C; Plantaz D
    Pediatrie; 1990; 45(9):619-23. PubMed ID: 2175425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.